Okklo life sciences was successful in obtaining a grant from Agentschap NL as a member of the IPC funding scheme.
In this program, SMEs are required to enter into collaborative projects around selected themes leading to innovations.
Okklo was the coordinating member for a group of five SMEs working in/around infectious diseases (e.g. malaria, Q-fever, TB).
Most of these SMEs were recently established as a spin-off from the former R&D site of MSD (Merck) in Oss, The Netherlands.
Partners in the collaborative project DxBOss are Avivia, Pharmacytics, PRRIL, TropIQ and okklo life sciences.